Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 7.87M | -- | 1953 |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 7.46M | -- | 1960 |
| Dr. Andrew J. Murphy Ph.D. | Executive Vice President of Research | 1.62M | 20.55M | 1959 |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 1.93M | 10.26M | 1973 |
| Mr. Christopher R. Fenimore CPA | Senior VP of Finance & CFO | -- | -- | 1971 |
| Ms. Patrice Gilooly | Senior Vice President of Quality Assurance & Operations | -- | -- | -- |
| Mr. Bob McCowan | Senior VP of IT & Chief Information Officer | -- | -- | -- |
| Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | -- | -- | -- |
| Mr. Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary | 1.68M | 22.34M | 1959 |
| Ms. Melissa Lozner | Senior VP & Chief Compliance Officer | -- | -- | -- |
Regeneron Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 14,165
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Corporate Governance
Upcoming Events
February 4, 2025 at 1:30 PM UTC
Regeneron Pharmaceuticals, Inc. Earnings Date
Recent Events
Recent Events Information Not Available